Purine and pyrimidine pathways as targets in plasmodium falciparum

Current Topics in Medicinal Chemistry

Volumn 11, Issue 16, 2011, Pages 2103-2115

  Cassera, María Belén ^a   Zhang, Yong ^a   Hazleton, Keith Z ^a   Schramm, Vern L ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Antimalarials; Immucillins; Malaria; Purines; Pyrimidines; Transition state analogues

Indexed keywords

4,6 DIAMINO 1,2 DIHYDRO 2,2 DIMETHYL 1 [3 (2,4,5 TRICHLOROPHENOXY)PROPOXY] 1,3,5 TRIAZINE; ADENOSINE DEAMINASE; ADENOSINE DEAMINASE INHIBITOR; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; CARBAMOYL PHOSPHATE SYNTHASE (GLUTAMINE HYDROLYSING); CARBAMOYL PHOSPHATE SYNTHASE (GLUTAMINE HYDROLYSING) INHIBITOR; COFORMYCIN; DIHYDROOROTASE; DIHYDROOROTASE INHIBITOR; DIHYDROOROTATE DEHYDROGENASE; DIHYDROOROTATE DEHYDROGENASE INHIBITOR; FORODESINE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE INHIBITOR; IMMUCILLIN DERIVATIVE; IMMUCILLIN G 5' PHOSPHATE; IMMUCILLIN H 5' PHOSPHATE; LEFLUNOMIDE; OROTATE PHOSPHORIBOSYLTRANSFERASE; OROTATE PHOSPHORIBOSYLTRANSFERASE INHIBITOR; PENTOSTATIN; PIRAZOFURIN; PROGUANIL; PURINE NUCLEOSIDE PHOSPHORYLASE; PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITOR; QUININE; UNCLASSIFIED DRUG; UNINDEXED DRUG; URACIL;

ANTIMALARIAL ACTIVITY; ARTICLE; BINDING AFFINITY; CONFORMATIONAL TRANSITION; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME SPECIFICITY; ERYTHROCYTE; HUMAN; IC 50; MALARIA; MOSQUITO; NONHUMAN; NUCLEIC ACID SYNTHESIS; PARASITE DEVELOPMENT; PLASMODIUM FALCIPARUM; PURINE METABOLISM; PYRIMIDINE METABOLISM; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; VECTOR CONTROL;

ANTIMALARIALS; BINDING SITES; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; MALARIA, FALCIPARUM; MODELS, MOLECULAR; PLASMODIUM FALCIPARUM; PROTEIN BINDING; PROTOZOAN PROTEINS; PURINE NUCLEOSIDES; PURINES; PYRIMIDINES; PYRIMIDINONES; PYRROLES; SUBSTRATE SPECIFICITY;

EID: 80051692910     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802611796575948     Document Type: Article

References (131)

1. Snow, R. W.; Guerra, C. A.; Noor, A. M.; Myint, H. Y.; Hay, S. I. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature, 2005, 434, 214-217.
2. Hyde, J. E. Drug-resistant malaria. Trends Parasitol, 2005, 21, 494-498.
3. Hyde, J. E. Drug-resistant malaria - an insight. Febs J., 2007, 274, 4688-4698.
4. de Koning, H. P.; Bridges, D. J.; Burchmore, R. J. S. Purine and pyrimidine transport in pathogenic protozoa: From biology to therapy. FEMS Microbiol. Rev., 2005, 29, 987-1020.
5. Hyde, J. E. Targeting purine and pyrimidine metabolism in human apicomplexan parasites. Curr. Drug Targets, 2007, 8, 31-47.
6. Reyes, P.; Rathod, P. K.; Sanchez, D. J.; Mrema, J. E.; Rieckmann, K. H.; Heidrich, H. G. Enzymes of purine and pyrimidine metabolism from the human malaria parasite, Plasmodium falciparum. Mol. Biochem. Parasitol, 1982, 5, 275-290.
7. Shi, W.; Ting, L. M.; Kicska, G. A.; Lewandowicz, A.; Tyler, P. C.; Evans, G. B.; Furneaux, R. H.; Kim, K.; Almo, S. C.; Schramm, V. L. Plasmodium falciparum purine nucleoside phosphorylase: crystal structures, immucillin inhibitors; dual catalytic function. J. Biol. Chem., 2004, 279, 18103-18106.
8. Gardner, M. J.; Hall, N.; Fung, E.; White, O.; Berriman, M.; Hyman, R. W.; Carlton, J. M.; Pain, A.; Nelson, K. E.; Bowman, S.; Paulsen, I. T.; James, K.; Eisen, J. A.; Rutherford, K.; Salzberg, S. L.; Craig, A.; Kyes, S.; Chan, M. S.; Nene, V.; Shallom, S. J.; Suh, B.; Peterson, J.; Angiuoli, S.; Pertea, M.; Allen, J.; Selengut, J.; Haft, D.; Mather, M. W.; Vaidya, A. B.; Martin, D. M.; Fairlamb, A. H.; Fraunholz, M. J.; Roos, D. S.; Ralph, S. A.; McFadden, G. I.; Cummings, L. M.; Subramanian, G. M.; Mungall, C.; Venter, J. C.; Carucci, D. J.; Hoffman, S. L.; Newbold, C.; Davis, R. W.; Fraser, C. M.; Barrell, B. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature, 2002, 419, 498-511.
9. Cassera, M. B.; Hazleton, K. Z.; Riegelhaupt, P. M.; Merino, E. F.; Luo, M.; Akabas, M. H.; Schramm, V. L. Erythrocytic adenosine monophosphate as an alternative purine source in Plasmodium falciparum. J. Biol. Chem., 2008, 283, 32889-32899.
10. Kicska, G. A.; Tyler, P. C.; Evans, G. B.; Furneaux, R. H.; Schramm, V. L.; Kim, K. Purine-less death in Plasmodium falciparum induced by immucillin-H, a transition state analogue of purine nucleoside phosphorylase. J. Biol. Chem., 2002, 277, 3226-3231.
11. Tyler, P. C.; Taylor, E. A.; Frohlich, R. F.; Schramm, V. L. Synthesis of 5'-methylthio coformycins: specific inhibitors for malarial adenosine deaminase. J. Am. Chem. Soc., 2007, 129, 6872-6879.
12. Webster, H. K.; Wiesmann, W. P.; Pavia, C. S. Adenosine deaminase in malaria infection: effect of 2'-deoxycoformycin in vivo. Adv. Exp. Med. Biol., 1984, 165 Pt A, 225-229.
13. Ho, M. C.; Cassera, M. B.; Madrid, D. C.; Ting, L. M.; Tyler, P. C.; Kim, K.; Almo, S. C.; Schramm, V. L. Structural and metabolic specificity of methylthiocoformycin for malarial adenosine deaminases. Biochemistry, 2009, 48, 9618-9626.
14. Li, C. M.; Tyler, P. C.; Furneaux, R. H.; Kicska, G.; Xu, Y.; Grubmeyer, C.; Girvin, M. E.; Schramm, V. L. Transition-state analogs as inhibitors of human and malarial hypoxanthine-guanine phosphoribosyltransferases. Nat. Struct. Biol., 1999, 6, 582-587.
15. Li, J.; Zhou, B. Biological actions of artemisinin: insights from medicinal chemistry studies. Molecules, 2010, 15, 1378-1397.
16. O'Neill, P. M.; Barton, V. E.; Ward, S. A. The molecular mechanism of action of artemisinin--the debate continues. Molecules, 2010, 15, 1705-1721.
17. Wolfenden, R. Transition state analogues for enzyme catalysis. Nature, 1969, 223, 704-705.
18. Schramm, V. L. Enzymatic transition state theory and transition state analogue design. J. Biol. Chem., 2007, 282, 28297-28300.
19. Schramm, V. L. Enzymatic transition state poise and transition state analogues. Acc. Chem. Res., 2003, 36, 588-596.
20. Singh, V.; Evans, G. B.; Lenz, D. H.; Mason, J. M.; Clinch, K.; Mee, S.; Painter, G. F.; Tyler, P. C.; Furneaux, R. H.; Lee, J. E.; Howell, P. L.; Schramm, V. L. Femtomolar transition state analogue inhibitors of 5'-methylthioadenosine/Sadenosylhomocysteine nucleosidase from Escherichia coli. J. Biol. Chem., 2005, 280, 18265-18273.
21. Lewandowicz, A.; Tyler, P. C.; Evans, G. B.; Furneaux, R. H.; Schramm, V. L. Achieving the ultimate physiological goal in transition state analogue inhibitors for purine nucleoside phosphorylase. J. Biol. Chem., 2003, 278, 31465-31468.
22. Schramm, V. L. Enzymatic transition states and transition state analog design. Annu. Rev. Biochem., 1998, 67, 693-720.
23. Schramm, V. L. Enzymatic transition states and transition state analogues. Curr. Opin. Struct. Biol., 2005, 15, 604-613.
24. Ting, L. M.; Shi, W.; Lewandowicz, A.; Singh, V.; Mwakingwe, A.; Birck, M. R.; Ringia, E. A.; Bench, G.; Madrid, D. C.; Tyler, P. C.; Evans, G. B.; Furneaux, R. H.; Schramm, V. L.; Kim, K. Targeting a novel Plasmodium falciparum purine recycling pathway with specific immucillins. J. Biol. Chem., 2005, 280, 9547-9554.
25. Trackman, P. C.; Abeles, R. H. Methionine synthesis from 5'-SMethylthioadenosine. Resolution of enzyme activities and identification of 1-phospho-5-S methylthioribulose. J. Biol. Chem., 1983, 258, 6717-6720.
26. Olszewski, K. L.; Morrisey, J. M.; Wilinski, D.; Burns, J. M.; Vaidya, A. B.; Rabinowitz, J. D.; Llinas, M. Host-parasite interactions revealed by Plasmodium falciparum metabolomics. Cell Host Microbe, 2009, 5, 191-199.
27. Luo, M.; Singh, V.; Taylor, E. A.; Schramm, V. L. Transition-state variation in human, bovine; Plasmodium falciparum adenosine deaminases. J. Am. Chem. Soc., 2007, 129, 8008-8017.
28. Daddona, P. E.; Wiesmann, W. P.; Milhouse, W.; Chern, J. W.; Townsend, L. B.; Hershfield, M. S.; Webster, H. K. Expression of human malaria parasite purine nucleoside phosphorylase in host enzyme-deficient erythrocyte culture. Enzyme characterization and identification of novel inhibitors. J. Biol. Chem., 1986, 261, 11667-11673.
29. Kicska, G. A.; Tyler, P. C.; Evans, G. B.; Furneaux, R. H.; Kim, K.; Schramm, V. L. Transition state analogue inhibitors of purine nucleoside phosphorylase from Plasmodium falciparum. J. Biol. Chem., 2002, 277, 3219-3225.
30. Markert, M. L. Purine nucleoside phosphorylase deficiency. Immunodefic. Rev., 1991, 3, 45-81.
31. Kline, P. C.; Schramm, V. L. Purine nucleoside phosphorylase. Catalytic mechanism and transition-state analysis of the arsenolysis reaction. Biochemistry, 1993, 32, 13212-13219.
32. Lewandowicz, A.; Schramm, V. L. Transition state analysis for human and Plasmodium falciparum purine nucleoside phosphorylases. Biochemistry, 2004, 43, 1458-1468.
33. Miles, R. W.; Tyler, P. C.; Furneaux, R. H.; Bagdassarian, C. K.; Schramm, V. L. One-third-the-sites transition-state inhibitors for purine nucleoside phosphorylase. Biochemistry, 1998, 37, 8615-8621.
34. Lewandowicz, A.; Shi, W.; Evans, G. B.; Tyler, P. C.; Furneaux, R. H.; Basso, L. A.; Santos, D. S.; Almo, S. C.; Schramm, V. L. Overthe-barrier transition state analogues and crystal structure with Mycobacterium tuberculosis purine nucleoside phosphorylase. Biochemistry, 2003, 42, 6057-6066.
35. Riegelhaupt, P. M.; Cassera, M. B.; Frohlich, R. F.; Hazleton, K. Z.; Hefter, J. J.; Schramm, V. L.; Akabas, M. H. Transport of purines and purine salvage pathway inhibitors by the Plasmodium falciparum equilibrative nucleoside transporter PfENT1. Mol. Biochem. Parasitol., 2010, 169, 40-49.
36. Martin, R. E.; Henry, R. I.; Abbey, J. L.; Clements, J. D.; Kirk, K. The 'permeome' of the malaria parasite: an overview of the membrane transport proteins of Plasmodium falciparum. Genome Biol., 2005, 6, R26.
37. Queen, S. A.; Vander Jagt, D.; Reyes, P. Properties and substrate specificity of a purine phosphoribosyltransferase from the human malaria parasite, Plasmodium falciparum. Mol. Biochem. Parasitol., 1988, 30, 123-133.
38. Vasanthakumar, G.; Davis, R. L., Jr.; Sullivan, M. A.; Donahue, J. P. Cloning and expression in Escherichia coli of a hypoxanthineguanine phosphoribosyltransferase-encoding cDNA from Plasmodium falciparum. Gene, 1990, 91, 63-69.
39. Keough, D. T.; Ng, A. L.; Winzor, D. J.; Emmerson, B. T.; de Jersey, J. Purification and characterization of Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase and comparison with the human enzyme. Mol. Biochem. Parasitol., 1999, 98, 29-41.
40. Raman, J.; Ashok, C. S.; Subbayya, S. I.; Anand, R. P.; Selvi, S. T.; Balaram, H. Plasmodium falciparum hypoxanthine guanine phosphoribosyltransferase. Stability studies on the productactivated enzyme. FEBS J., 2005, 272, 1900-1911.
41. Sujay Subbayya, I. N.; Balaram, H. Evidence for multiple active states of Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase. Biochem. Biophys. Res. Commun., 2000, 279, 433-437.
42. Zhang, Y.; Luo, M.; Schramm, V. L. Transition states of Plasmodium falciparum and human orotate phosphoribosyltransferases. J. Am. Chem. Soc., 2009, 131, 4685-4694.
43. Tao, W.; Grubmeyer, C.; Blanchard, J. S. Transition state structure of Salmonella typhimurium orotate phosphoribosyltransferase. Biochemistry, 1996, 35, 14-21.
44. Shi, W.; Li, C. M.; Tyler, P. C.; Furneaux, R. H.; Grubmeyer, C.; Schramm, V. L.; Almo, S. C. The 2.0 Å structure of human hypoxanthine-guanine phosphoribosyltransferase in complex with a transition-state analog inhibitor. Nat. Struct. Biol., 1999, 6, 588-593.
45. Shi, W.; Li, C. M.; Tyler, P. C.; Furneaux, R. H.; Cahill, S. M.; Girvin, M. E.; Grubmeyer, C.; Schramm, V. L.; Almo, S. C. The 2.0 Å structure of malarial purine phosphoribosyltransferase in complex with a transition-state analogue inhibitor. Biochemistry, 1999, 38, 9872-9880.
46. Keough, D. T.; Hockova, D.; Holy, A.; Naesens, L. M.; Skinner-Adams, T. S.; Jersey, J.; Guddat, L. W. Inhibition of hypoxanthineguanine phosphoribosyltransferase by acyclic nucleoside phosphonates: a new class of antimalarial therapeutics. J. Med. Chem., 2009, 52, 4391-4399.
47. Bhat, J. Y.; Shastri, B. G.; Balaram, H. Kinetic and biochemical characterization of Plasmodium falciparum GMP synthetase. Biochem. J., 2008, 409, 263-273.
48. Eaazhisai, K.; Jayalakshmi, R.; Gayathri, P.; Anand, R. P.; Sumathy, K.; Balaram, H.; Murthy, M. R. Crystal structure of fully ligated adenylosuccinate synthetase from Plasmodium falciparum. J. Mol. Biol., 2004, 335, 1251-1264.
49. Raman, J.; Mehrotra, S.; Anand, R. P.; Balaram, H. Unique kinetic mechanism of Plasmodium falciparum adenylosuccinate synthetase. Mol. Biochem. Parasitol., 2004, 138, 1-8.
50. Bulusu, V.; Srinivasan, B.; Bopanna, M. P.; Balaram, H. Elucidation of the substrate specificity, kinetic and catalytic mechanism of adenylosuccinate lyase from Plasmodium falciparum. Biochim. Biophys. Acta, 2009, 1794, 642-654.
51. Gero, A. M.; Brown, G. V.; O'Sullivan, W. J. Pyrimidine de novo synthesis during the life cycle of the intraerythrocytic stage of Plasmodium falciparum. J. Parasitol., 1984, 70, 536-541.
52. Flores, M. V.; O'Sullivan, W. J.; Stewart, T. S. Characterisation of the carbamoyl phosphate synthetase gene from Plasmodium falciparum. Mol. Biochem. Parasitol., 1994, 68, 315-318.
53. Flores, M. V.; Atkins, D.; Wade, D.; O'Sullivan, W. J.; Stewart, T. S. Inhibition of Plasmodium falciparum proliferation in vitro by ribozymes. J. Biol. Chem., 1997, 272, 16940-16945.
54. Hendry, P.; McCall, M. J.; Stewart, T. S.; Lockett, T. J. Redesigned and chemically-modified hammerhead ribozymes with improved activity and serum stability. BMC Chem. Biol., 2004, 4, 1.
55. Alvarez-Salas, L. M. Nucleic acids as therapeutic agents. Curr. Top. Med. Chem., 2008, 8, 1379-1404.
56. Simmer, J. P.; Kelly, R. E.; Rinker, A. G., Jr.; Zimmermann, B. H.; Scully, J. L.; Kim, H.; Evans, D. R. Mammalian dihydroorotase: nucleotide sequence, peptide sequences; evolution of the dihydroorotase domain of the multifunctional protein CAD. Proc. Natl. Acad. Sci. USA, 1990, 87, 174-178.
57. Krungkrai, S. R.; Wutipraditkul, N.; Krungkrai, J. Dihydroorotase of human malarial parasite Plasmodium falciparum differs from host enzyme. Biochem. Biophys. Res. Commun., 2008, 366, 821-826.
58. Seymour, K. K.; Lyons, S. D.; Phillips, L.; Rieckmann, K. H.; Christopherson, R. I. Cytotoxic effects of inhibitors of de novo pyrimidine biosynthesis upon Plasmodium falciparum. Biochemistry, 1994, 33, 5268-5274.
59. Manthey, M. K.; Huang, D. T.; Bubb, W. A.; Christopherson, R. I. Synthesis and enzymic evaluation of 4-mercapto-6-oxo-1, 4-azaphosphinane-2-carboxylic acid 4-oxide as an inhibitor of mammalian dihydroorotase. J. Med. Chem., 1998, 41, 4550-4555.
60. Adams, J. L.; Meek, T. D.; Mong, S. M.; Johnson, R. K.; Metcalf, B. W. cis-4-Carboxy-6-(mercaptomethyl)-3,4,5,6-tetrahydropyrimidin-2(1 H)-one, a potent inhibitor of mammalian dihydroorotase. J. Med. Chem., 1988, 31, 1355-1359.
61. Christopherson, R. I.; Schmalzl, K. J.; Szabados, E.; Goodridge, R. J.; Harsanyi, M. C.; Sant, M. E.; Algar, E. M.; Anderson, J. E.; Armstrong, A.; Sharma, S.C., et al. Mercaptan and dicarboxylate inhibitors of hamster dihydroorotase. Biochemistry, 1989, 28, 463-470.
62. Jones, M. E. Pyrimidine nucleotide biosynthesis in animals: genes, enzymes; regulation of UMP biosynthesis. Annu. Rev. Biochem., 1980, 49, 253-279.
63. Vaidya, A. B.; Mather, M. W. Mitochondrial evolution and functions in malaria parasites. Annu. Rev. Microbiol., 2009, 63, 249-267.
64. Williamson, R. A.; Yea, C. M.; Robson, P. A.; Curnock, A. P.; Gadher, S.; Hambleton, A. B.; Woodward, K.; Bruneau, J. M.; Hambleton, P.; Spinella-Jaegle, S.; Morand, P.; Courtin, O.; Sautes, C.; Westwood, R.; Hercend, T.; Kuo, E. A.; Ruuth, E. Dihydroorotate dehydrogenase is a target for the biological effects of leflunomide. Transplant Proc., 1996, 28, 3088-3091.
65. Fox, R. I.; Herrmann, M. L.; Frangou, C. G.; Wahl, G. M.; Morris, R. E.; Strand, V.; Kirschbaum, B. J. Mechanism of action for leflunomide in rheumatoid arthritis. Clin. Immunol., 1999, 93, 198-208.
66. Williamson, R. A.; Yea, C. M.; Robson, P. A.; Curnock, A. P.; Gadher, S.; Hambleton, A. B.; Woodward, K.; Bruneau, J. M.; Hambleton, P.; Moss, D.; Thomson, T. A.; Spinella-Jaegle, S.; Morand, P.; Courtin, O.; Sautes, C.; Westwood, R.; Hercend, T.; Kuo, E. A.; Ruuth, E. Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound. J. Biol. Chem., 1995, 270, 22467-22472.
67. Chen, S. F.; Ruben, R. L.; Dexter, D. L. Mechanism of action of the novel anticancer agent 6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarbo xylic acid sodium salt (NSC 368390): inhibition of de novo pyrimidine nucleotide biosynthesis. Cancer Res., 1986, 46, 5014-5019.
68. McLean, J. E.; Neidhardt, E. A.; Grossman, T. H.; Hedstrom, L. Multiple inhibitor analysis of the brequinar and leflunomide binding sites on human dihydroorotate dehydrogenase. Biochemistry, 2001, 40, 2194-2200.
69. Davies, M.; Heikkila, T.; McConkey, G. A.; Fishwick, C. W.; Parsons, M. R.; Johnson, A. P. Structure-based design, synthesis; characterization of inhibitors of human and Plasmodium falciparum dihydroorotate dehydrogenases. J. Med. Chem., 2009, 52, 2683-2693.
70. Baldwin, J.; Michnoff, C. H.; Malmquist, N. A.; White, J.; Roth, M. G.; Rathod, P. K.; Phillips, M. A. High-throughput screening for potent and selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. J. Biol. Chem., 2005, 280, 21847-21853.
71. Patel, V.; Booker, M.; Kramer, M.; Ross, L.; Celatka, C. A.; Kennedy, L. M.; Dvorin, J. D.; Duraisingh, M. T.; Sliz, P.; Wirth, D. F.; Clardy, J. Identification and characterization of small molecule inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. J. Biol. Chem., 2008, 283, 35078-35085.
72. Phillips, M. A.; Gujjar, R.; Malmquist, N. A.; White, J.; El Mazouni, F.; Baldwin, J.; Rathod, P. K. Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors with potent and selective activity against the malaria parasite Plasmodium falciparum. J. Med. Chem., 2008, 51, 3649-3653.
73. Gujjar, R.; Marwaha, A.; El Mazouni, F.; White, J.; White, K. L.; Creason, S.; Shackleford, D. M.; Baldwin, J.; Charman, W. N.; Buckner, F. S.; Charman, S.; Rathod, P. K.; Phillips, M. A. Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice. J. Med. Chem., 2009, 52, 1864-1872.
74. Heikkila, T.; Ramsey, C.; Davies, M.; Galtier, C.; Stead, A. M.; Johnson, A. P.; Fishwick, C. W.; Boa, A. N.; McConkey, G. A. Design and synthesis of potent inhibitors of the malaria parasite dihydroorotate dehydrogenase. J. Med. Chem., 2007, 50, 186-191.
75. Hudson, A. T. Atovaquone - a novel broad-spectrum anti-infective drug. Parasitol. Today, 1993, 9, 66-68.
76. Christopherson, R. I.; Lyons, S. D.; Wilson, P. K. Inhibitors of de novo nucleotide biosynthesis as drugs. Acc. Chem. Res., 2002, 35, 961-971.
77. Hammond, D. J.; Burchell, J. R.; Pudney, M. Inhibition of pyrimidine biosynthesis de novo in Plasmodium falciparum by 2-(4-t-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone in vitro. Mol. Biochem. Parasitol., 1985, 14, 97-109.
78. Srivastava, I. K.; Rottenberg, H.; Vaidya, A. B. Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite. J. Biol. Chem., 1997, 272, 3961-3966.
79. Fry, M.; Pudney, M. Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4'-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80). Biochem. Pharmacol., 1992, 43, 1545-1553.
80. Painter, H. J.; Morrisey, J. M.; Mather, M. W.; Vaidya, A. B. Specific role of mitochondrial electron transport in blood-stage Plasmodium falciparum. Nature, 2007, 446, 88-91.
81. Suchi, M.; Mizuno, H.; Kawai, Y.; Tsuboi, T.; Sumi, S.; Okajima, K.; Hodgson, M. E.; Ogawa, H.; Wada, Y. Molecular cloning of the human UMP synthase gene and characterization of point mutations in two hereditary orotic aciduria families. Am. J. Hum. Genet., 1997, 60, 525-539.
82. Yablonski, M. J.; Pasek, D. A.; Han, B. D.; Jones, M. E.; Traut, T. W. Intrinsic activity and stability of bifunctional human UMP synthase and its two separate catalytic domains, orotate phosphoribosyltransferase and orotidine-5'-phosphate decarboxylase. J. Biol. Chem., 1996, 271, 10704-10708.
83. Krungkrai, S. R.; Aoki, S.; Palacpac, N. M.; Sato, D.; Mitamura, T.; Krungkrai, J.; Horii, T. Human malaria parasite orotate phosphoribosyltransferase: functional expression, characterization of kinetic reaction mechanism and inhibition profile. Mol. Biochem. Parasitol., 2004, 134, 245-255.
84. Queen, S. A.; Jagt, D. L.; Reyes, P. In vitro susceptibilities of Plasmodium falciparum to compounds which inhibit nucleotide metabolism. Antimicrob. Agents Chemother., 1990, 34, 1393-1398.
85. Rathod, P. K.; Khatri, A.; Hubbert, T.; Milhous, W. K. Selective activity of 5-fluoroorotic acid against Plasmodium falciparum in vitro. Antimicrob. Agents Chemother., 1989, 33, 1090-1094.
86. Krungkrai, J.; Krungkrai, S. R.; Phakanont, K. Antimalarial activity of orotate analogs that inhibit dihydroorotase and dihydroorotate dehydrogenase. Biochem. Pharmacol., 1992, 43, 1295-1301.
87. Rathod, P. K.; Khosla, M.; Gassis, S.; Young, R. D.; Lutz, C. Selection and characterization of 5-fluoroorotate-resistant Plasmodium falciparum. Antimicrob. Agents Chemother., 1994, 38, 2871-2876.
88. Scott, H. V.; Gero, A. M.; O'Sullivan, W. J. In vitro inhibition of Plasmodium falciparum by pyrazofurin, an inhibitor of pyrimidine biosynthesis de novo. Mol. Biochem. Parasitol., 1986, 18, 3-15.
89. Suttle, D. P.; Stark, G. R. Coordinate overproduction of orotate phosphoribosyltransferase and orotidine-5'-phosphate decarboxylase in hamster cells resistant to pyrazofurin and 6-azauridine. J. Biol. Chem., 1979, 254, 4602-4607.
90. Dix, D. E.; Lehman, C. P.; Jakubowski, A.; Moyer, J. D.; Handschumacher, R. E. Pyrazofurin metabolism, enzyme inhibition; resistance in L5178Y cells. Cancer Res., 1979, 39, 4485-4490.
91. Suttle, D. P. Increased levels of UMP synthase protein and mRNA in pyrazofurin-resistant rat hepatoma cells. J. Biol. Chem., 1983, 258, 7707-7713.
92. Radzicka, A.; Wolfenden, R. A proficient enzyme. Science, 1995, 267, 90-93.
93. Miller, B. G.; Wolfenden, R. Catalytic proficiency: the unusual case of OMP decarboxylase. Annu. Rev. Biochem., 2002, 71, 847-885.
94. Langley, D. B.; Shojaei, M.; Chan, C.; Lok, H. C.; Mackay, J. P.; Traut, T. W.; Guss, J. M.; Christopherson, R. I. Structure and inhibition of orotidine 5'-monophosphate decarboxylase from Plasmodium falciparum. Biochemistry, 2008, 47, 3842-3854.
95. Bello, A. M.; Poduch, E.; Fujihashi, M.; Amani, M.; Li, Y.; Crandall, I.; Hui, R.; Lee, P. I.; Kain, K. C.; Pai, E. F.; Kotra, L. P. A potent, covalent inhibitor of orotidine 5'-monophosphate decarboxylase with antimalarial activity. J. Med. Chem., 2007, 50, 915-921.
96. Bello, A. M.; Poduch, E.; Liu, Y.; Wei, L.; Crandall, I.; Wang, X.; Dyanand, C.; Kain, K. C.; Pai, E. F.; Kotra, L. P. Structure-activity relationships of C6-uridine derivatives targeting plasmodia orotidine monophosphate decarboxylase. J. Med. Chem., 2008, 51, 439-448.
97. Levine, H. L.; Brody, R. S.; Westheimer, F. H. Inhibition of orotidine-5'-phosphate decarboxylase by 1-(5'-phospho-beta-dribofuranosyl) barbituric acid, 6-azauridine 5'-phosphate; uridine 5'-phosphate. Biochemistry, 1980, 19, 4993-4999.
98. Miller, B. G.; Traut, T. W.; Wolfenden, R. Effects of substrate binding determinants in the transition state for orotidine 5 '- monophosphate decarboxylase. Bioorg. Chem., 1998, 26, 283-288.
99. Vertessy, B. G.; Toth, J. Keeping uracil out of DNA: physiological role, structure and catalytic mechanism of dUTPases. Acc. Chem. Res., 2009, 42, 97-106.
100. Whittingham, J. L.; Leal, I.; Nguyen, C.; Kasinathan, G.; Bell, E.; Jones, A. F.; Berry, C.; Benito, A.; Turkenburg, J. P.; Dodson, E. J.; Ruiz Perez, L. M.; Wilkinson, A. J.; Johansson, N. G.; Brun, R.; Gilbert, I. H.; Gonzalez Pacanowska, D.; Wilson, K. S. dUTPase as a platform for antimalarial drug design: structural basis for the selectivity of a class of nucleoside inhibitors. Structure, 2005, 13, 329-338.
101. Quesada-Soriano, I.; Casas-Solvas, J. M.; Recio, E.; Ruiz-Perez, L. M.; Vargas-Berenguel, A.; Gonzalez-Pacanowska, D.; Garcia-Fuentes, L. Kinetic properties and specificity of trimeric Plasmodium falciparum and human dUTPases. Biochimie, 92, 178-186.
102. Nguyen, C.; Kasinathan, G.; Leal-Cortijo, I.; Musso-Buendia, A.; Kaiser, M.; Brun, R.; Ruiz-Perez, L. M.; Johansson, N. G.; Gonzalez-Pacanowska, D.; Gilbert, I. H. Deoxyuridine triphosphate nucleotidohydrolase as a potential antiparasitic drug target. J. Med. Chem., 2005, 48, 5942-5954.
103. Nguyen, C.; Ruda, G. F.; Schipani, A.; Kasinathan, G.; Leal, I.; Musso-Buendia, A.; Kaiser, M.; Brun, R.; Ruiz-Perez, L. M.; Sahlberg, B. L.; Johansson, N. G.; Gonzalez-Pacanowska, D.; Gilbert, I. H. Acyclic nucleoside analogues as inhibitors of Plasmodium falciparum dUTPase. J. Med. Chem., 2006, 49, 4183-4195.
104. McCarthy, O.; Musso-Buendia, A.; Kaiser, M.; Brun, R.; Ruiz- Perez, L. M.; Johansson, N. G.; Pacanowska, D. G.; Gilbert, I. H. Design, synthesis and evaluation of novel uracil acetamide derivatives as potential inhibitors of Plasmodium falciparum dUTP nucleotidohydrolase. Eur. J. Med. Chem., 2009, 44, 678-688.
105. Nzila, A. Inhibitors of de novo folate enzymes in Plasmodium falciparum. Drug Discov. Today, 2006, 11, 939-944.
106. Dasgupta, T.; Anderson, K. S. Probing the role of parasite-specific, distant structural regions on communication and catalysis in the bifunctional thymidylate synthase-dihydrofolate reductase from Plasmodium falciparum. Biochemistry, 2008, 47, 1336-1345.
107. Ivanetich, K. M.; Santi, D. V. Thymidylate synthase-dihydrofolate reductase in protozoa. Exp. Parasitol., 1990, 70, 367-371.
108. Yuvaniyama, J.; Chitnumsub, P.; Kamchonwongpaisan, S.; Vanichtanankul, J.; Sirawaraporn, W.; Taylor, P.; Walkinshaw, M. D.; Yuthavong, Y. Insights into antifolate resistance from malarial DHFR-TS structures. Nat. Struct. Biol., 2003, 10, 357-365.
109. Anderson, A. C. Targeting DHFR in parasitic protozoa. Drug Discov. Today, 2005, 10, 121-128.
110. Winstanley, P. A.; Mberu, E. K.; Szwandt, I. S.; Breckenridge, A. M.; Watkins, W. M. In vitro activities of novel antifolate drug combinations against Plasmodium falciparum and human granulocyte CFUs. Antimicrob. Agents Chemother., 1995, 39, 948-952.
111. Hankins, E. G.; Warhurst, D. C.; Sibley, C. H. Novel alleles of the Plasmodium falciparum dhfr highly resistant to pyrimethamine and chlorcycloguanil, but not WR99210. Mol. Biochem. Parasitol., 2001, 117, 91-102.
112. Hekmat-Nejad, M.; Rathod, P. K. Plasmodium falciparum: kinetic interactions of WR99210 with pyrimethamine-sensitive and pyrimethamine-resistant dihydrofolate reductase. Exp. Parasitol., 1997, 87, 222-228.
113. Warhurst, D. C. Resistance to antifolates in Plasmodium falciparum, the causative agent of tropical malaria. Sci. Prog., 2002, 85, 89-111.
114. Canfield, C. J.; Milhous, W. K.; Ager, A. L.; Rossan, R. N.; Sweeney, T. R.; Lewis, N. J.; Jacobus, D. P. PS-15: a potent, orally active antimalarial from a new class of folic acid antagonists. Am. J. Trop. Med. Hyg., 1993, 49, 121-126.
115. Rieckmann, K. H.; Yeo, A. E.; Edstein, M. D. Activity of PS-15 and its metabolite, WR99210, against Plasmodium falciparum in an in vivo-in vitro model. Trans. R. Soc. Trop. Med. Hyg., 1996, 90, 568-571.
116. Kamchonwongpaisan, S.; Quarrell, R.; Charoensetakul, N.; Ponsinet, R.; Vilaivan, T.; Vanichtanankul, J.; Tarnchompoo, B.; Sirawaraporn, W.; Lowe, G.; Yuthavong, Y. Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities. J. Med. Chem., 2004, 47, 673-680.
117. Sirichaiwat, C.; Intaraudom, C.; Kamchonwongpaisan, S.; Vanichtanankul, J.; Thebtaranonth, Y.; Yuthavong, Y. Target guided synthesis of 5-benzyl-2,4-diamonopyrimidines: their antimalarial activities and binding affinities to wild type and mutant dihydrofolate reductases from Plasmodium falciparum. J. Med. Chem., 2004, 47, 345-354.
118. Dasgupta, T.; Chitnumsub, P.; Kamchonwongpaisan, S.; Maneeruttanarungroj, C.; Nichols, S. E.; Lyons, T. M.; Tirado-Rives, J.; Jorgensen, W. L.; Yuthavong, Y.; Anderson, K. S. Exploiting structural analysis, in silico screening; serendipity to identify novel inhibitors of drug-resistant falciparum malaria. ACS Chem. Biol., 2009, 4, 29-40.
119. Barker, R. H., Jr.; Metelev, V.; Rapaport, E.; Zamecnik, P. Inhibition of Plasmodium falciparum malaria using antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA, 1996, 93, 514-518.
120. Van Daele, I.; Munier-Lehmann, H.; Hendrickx, P. M.; Marchal, G.; Chavarot, P.; Froeyen, M.; Qing, L.; Martins, J. C.; Van Calenbergh, S. Synthesis and biological evaluation of bicyclic nucleosides as inhibitors of M. tuberculosis thymidylate kinase. Chem. Med. Chem., 2006, 1, 1081-1090.
121. Van Daele, I.; Munier-Lehmann, H.; Froeyen, M.; Balzarini, J.; Van Calenbergh, S. Rational design of 5'-thiourea-substituted alpha-thymidine analogues as thymidine monophosphate kinase inhibitors capable of inhibiting mycobacterial growth. J. Med. Chem., 2007, 50, 5281-5292.
122. Kandeel, M.; Kitade, Y. Molecular characterization, heterologous expression and kinetic analysis of recombinant Plasmodium falciparum thymidylate kinase. J. Biochem., 2008, 144, 245-250.
123. Kandeel, M.; Ando, T.; Kitamura, Y.; Abdel-Aziz, M.; Kitade, Y. Mutational, inhibitory and microcalorimetric analyses of Plasmodium falciparum TMP kinase. Implications for drug discovery. Parasitology, 2009, 136, 11-25.
124. Yuan, P.; Hendriks, E. F.; Fernandez, H. R.; O'Sullivan, W. J.; Stewart, T. S. Functional expression of the gene encoding cytidine triphosphate synthetase from Plasmodium falciparum which contains two novel sequences that are potential antimalarial targets. Mol. Biochem. Parasitol., 2005, 143, 200-208.
125. Hendriks, E. F.; O'Sullivan, W. J.; Stewart, T. S. Molecular cloning and characterization of the Plasmodium falciparum cytidine triphosphate synthetase gene. Biochim. Biophys Acta, 1998, 1399, 213-218.
126. Kang, G. J.; Cooney, D. A.; Moyer, J. D.; Kelley, J. A.; Kim, H. Y.; Marquez, V. E.; Johns, D. G. Cyclopentenylcytosine triphosphate. Formation and inhibition of CTP synthetase. J. Biol. Chem., 1989, 264, 713-718.
127. McPartland, R. P.; Wang, M. C.; Bloch, A.; Weinfeld, H. Cytidine 5'-triphosphate synthetase as a target for inhibition by the antitumor agent 3-deazauridine. Cancer Res., 1974, 34, 3107-3111.
128. Viola, J. J.; Agbaria, R.; Walbridge, S.; Oshiro, E. M.; Johns, D. G.; Kelley, J. A.; Oldfield, E. H.; Ram, Z. In situ cyclopentenyl cytosine infusion for the treatment of experimental brain tumors. Cancer Res., 1995, 55, 1306-1309.
129. Yee, L. K.; Allegra, C. J.; Trepel, J. B.; Grem, J. L. Metabolism and RNA incorporation of cyclopentenyl cytosine in human colorectal cancer cells. Biochem. Pharmacol., 1992, 43, 1587-1599.
130. Gao, W. Y.; Johns, D. G.; Mitsuya, H. Potentiation of the anti-HIV activity of zalcitabine and lamivudine by a CTP synthase inhibitor, 3-deazauridine. Nucleosides Nucleotides Nucleic Acids, 2000, 19, 371-377.
131. Savickiene, J.; Gineitis, A. 3-Deazauridine triggers dose-dependent apoptosis in myeloid leukemia cells and enhances retinoic acidinduced granulocytic differentiation of HL-60 cells. Int. J. Biochem. Cell Biol., 2003, 35, 1482-1494.